Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice
暂无分享,去创建一个
V. Sukhatme | M. Schmelzle | A. Usheva | S. Robson | E. Csizmadia | W. Junger | E. Tapper | P. Seth | G. Baffy | Yan Wu | Xiaofeng Sun | Lihui Han | Linglin Li | Shu Bian
[1] T. Luedde,et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development , 2011, Nature.
[2] V. Bohr,et al. Metabolism, Genomics, and DNA Repair in the Mouse Aging Liver , 2011, Current gerontology and geriatrics research.
[3] S. Robson,et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. , 2011, Neoplasia.
[4] R. Lenkinski,et al. On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. , 2011, Neoplasia.
[5] Tak W. Mak,et al. The ER UDPase ENTPD5 Promotes Protein N-Glycosylation, the Warburg Effect, and Proliferation in the PTEN Pathway , 2010, Cell.
[6] Takashi Murakami,et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. , 2010, Gastroenterology.
[7] D. Candinas,et al. Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice , 2010, Hepatology.
[8] Jing Chen,et al. Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.
[9] J. Kramer,et al. Ectonucleoside Triphosphate Diphosphohydrolase Type 5 (Entpd5)-Deficient Mice Develop Progressive Hepatopathy, Hepatocellular Tumors, and Spermatogenic Arrest , 2009, Veterinary pathology.
[10] W. Linehan,et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.
[11] Derek Y. Chiang,et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.
[12] D. Candinas,et al. Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration. , 2008, Gastroenterology.
[13] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[14] W. Gerald,et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.
[15] D. Candinas,et al. Natural killer T cell dysfunction in CD39‐null mice protects against concanavalin A–induced hepatitis , 2008, Hepatology.
[16] K. Kotani,et al. Deletion of Cd39/Entpd1 Results in Hepatic Insulin Resistance , 2008, Diabetes.
[17] Y. Banz,et al. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism. , 2008, Frontiers in bioscience : a journal and virtual library.
[18] Robin Mathew,et al. Role of autophagy in cancer , 2007, Nature Reviews Cancer.
[19] V. Mootha,et al. mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.
[20] S. Robson,et al. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. , 2007, The American journal of pathology.
[21] Linda Yip,et al. ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.
[22] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[23] A. Usheva,et al. RanBPM associates with CD39 and modulates ecto-nucleotidase activity. , 2006, The Biochemical journal.
[24] Y. Ben-Neriah,et al. NF-κB inhibition: A double-edged sword in cancer? , 2006 .
[25] J. Thiran,et al. Morphological Classification of Mouse Liver Tumors Based on Biological Characteristics , 2006 .
[26] Y. Ben-Neriah,et al. NF-kappaB inhibition: a double-edged sword in cancer? , 2006, European journal of cancer.
[27] Raymond Sawaya,et al. The role of autophagy in cancer development and response to therapy , 2005, Nature Reviews Cancer.
[28] P. White,et al. Regulation of Human Hepatocytes by P2Y Receptors: Control of Glycogen Phosphorylase, Ca2+, and Mitogen-Activated Protein Kinases , 2005, Journal of Pharmacology and Experimental Therapeutics.
[29] S. Robson,et al. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. , 2005, Seminars in thrombosis and hemostasis.
[30] R. Rodnight,et al. ERK, PKC and PI3K/Akt Pathways Mediate Extracellular ATP and Adenosine-Induced Proliferation of U138-MG Human Glioma Cell Line , 2005, Oncology.
[31] M. Bjornsti,et al. The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.
[32] Vijaya R Arjunan,et al. Extracellular ATP activates c‐jun N‐terminal kinase signaling and cell cycle progression in hepatocytes , 2004, Hepatology.
[33] Hong Zhang,et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. , 2003, Cancer cell.
[34] Patricia D. Christie,et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 1999, Nature Medicine.
[35] S. Goldfarb,et al. Hepatocarcinogenesis in the mouse. Combined morphologic-stereologic studies. , 1983, The American journal of pathology.